Opinion|Videos|October 4, 2024
Treatment Regimen Considerations
Panelists discuss how various patient characteristics, including age, fitness level, cytogenetic risk, and comorbidities, influence their decision to use more intensive quadruplet regimens like D-VRd (daratumumab plus bortezomib, lenalidomide, and dexamethasone) vs standard triplet regimens, such as VRd or KRd (carfilzomib, lenalidomide, and dexamethasone) in transplant-eligible multiple myeloma patients, while also considering administration logistics and supportive care requirements
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What factors around administration logistics and supportive care requirements (eg, premedications, infusion reactions) do you consider when sequencing regimens for transplant-eligible patients?
- (Dr Adams) What patient characteristics would lead you to consider a quadruplet regimen like D-VRd (daratumumab plus bortezomib, lenalidomide, and dexamethasone) compared with a triplet regimen like VRd or KRd (carfilzomib, lenalidomide, and dexamethasone)?
Advertisement
Related to this article
Persistent symptoms can complicate life after a multiple myeloma treatment response, making routine symptom assessment and targeted supportive care essential.
Advertisement
Advertisement
Trending on Pharmacy Times
1
CVS Health to Split Into 2 Public Companies, Separating Retail and Specialty Pharmacy
2
Community Pharmacists Guide Patients New to Glucose Monitoring
3
Is Less More? Comparing Metronidazole Dosing in Confirmed Anaerobic Infections
4
Two Gene Therapy Approvals Expand Options for Rare Immune Disorders as Access Challenges Persist
5